Previous 10 | Next 10 |
The following slide deck was published by KalVista Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kalvista Pharmaceuticals (KALV) Investor Presentation - Slideshow
After completing a positive End-of-Phase 2 meeting with the FDA, KalVista Pharmaceuticals (NASDAQ:KALV) has decided to begin dosing in Q1 2022 for its Phase 3 trial designed to evaluate KVD900 as an oral therapy for hereditary angioedema (HAE). According to meeting minutes, the regulator...
– Positive End-of-Phase 2 Meeting Completed – – Phase 3 Trial Dosing Expected Q1 2022 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of ...
– KVD900 Phase 2 data presented at American College of Allergy, Asthma & Immunology Annual Scientific Meeting – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializati...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Confe...
– US Site Initiations Ongoing – – Regulatory Submissions Complete for All Countries Participating in Trial – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
– KVD824 Clinical Trial Regulatory Approvals in Canada, Australia, and the UK – – Response Submitted to FDA on IND Requests for KVD824 Phase 2 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 20,000 shares of KalVista common stock on August 3, 2021 as inducement...
KalVista Pharmaceticals (KALV): Q4 GAAP EPS of -$0.65 misses by $0.10.Cash, cash equivalents and marketable securities were $248.9M as of April 30, 2021, compared to $67.7M as of April 30, 2020. Press Release For further details see: KalVista Pharmaceticals EPS misses by $0.10
KalVista Pharmaceuticals (KALV) presents data for its oral drug candidates at the European Academy of Allergy and Clinical Immunology ((EAACI)) Congress.Data presentations include Phase 2 data for KVD900 for oral on-demand treatment of hereditary angioedema ((HAE)) attacks. The presented data...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...